NCT06716606View on ClinicalTrials.gov

A Study to Investigate the Long-term Safety and Efficacy of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease

PHASE3RecruitingINTERVENTIONAL
Enrollment

225

Participants

Timeline

Start Date

December 12, 2024

Primary Completion Date

July 19, 2028

Study Completion Date

January 8, 2030

Conditions
Bronchial Diseases
Interventions
DRUG

Belimumab

Belimumab will be administered.

Trial Locations (6)

100020

RECRUITING

GSK Investigational Site, Beijing

412007

RECRUITING

GSK Investigational Site, Zhuzhou

C1015ABO

RECRUITING

GSK Investigational Site, Ciudad Autonoma Buenos Aires

060-8648

RECRUITING

GSK Investigational Site, Hokkaido

113-8603

RECRUITING

GSK Investigational Site, Tokyo

Unknown

RECRUITING

GSK Investigational Site, Yongsan-Ku Seoul

Sponsors

Lead Sponsor

GlaxoSmithKline

Collaborators (1)

ICON plc
All Listed Sponsors
collaborator

ICON plc

INDUSTRY

lead

GlaxoSmithKline

INDUSTRY

NCT06716606 - A Study to Investigate the Long-term Safety and Efficacy of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease | Biotech Hunter | Biotech Hunter